July 5, 2016 — AtriCure Inc. announced that it has received CE Mark for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System, which offers increased functionality to occlude the LAA during minimally-invasive surgical (MIS) procedures. The device was previously launched in April 2016 with U.S. Food and Drug Administration (FDA) 510(k) clearance in the United States.
The addition of the AtriClip PRO2 device has expanded the left atrial appendage product offerings and now provides an ambidextrous locking and trigger-style clip closing mechanism, handle-based active articulation levers and a hoopless end effector. These features have improved the ease of use and time it takes to manage the left atrial appendage.
For more information: www.atricure.com
August 31, 2023 
